NCT01695460View on ClinicalTrials.gov

A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Migraine According to International Headache Society (IHS) Criteria (ICHD-II)
Interventions
DRUG

D3 Vitamin ®

"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."

DRUG

Placebo

Trial Locations (2)

9000

CCBR Aalborg A/S, Aalborg

9220

Aalborg University, Aalborg

All Listed Sponsors
collaborator

CCBR Aalborg A/S, Aalborg, Denmark

UNKNOWN

collaborator

Aalborg University Hospital

OTHER

lead

Aalborg University

OTHER

NCT01695460 - A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine | Biotech Hunter | Biotech Hunter